Ardent Health Partners, Inc. (ARDT)vsEli Lilly and Company (LLY)
ARDT
Ardent Health Partners, Inc.
$10.72
+0.28%
HEALTHCARE · Cap: $1.57B
LLY
Eli Lilly and Company
$1,138.34
+0.15%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1144% more annual revenue ($79.67B vs $6.41B). LLY leads profitability with a 33.5% profit margin vs 1.2%. ARDT trades at a lower P/E of 19.6x. LLY earns a higher WallStSmart Score of 76/100 (B+).
ARDT
Hold40
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of 7.7% — below average capital efficiency
1.2% margin — thin
Operating margin of 3.4%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 30.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARDT
The strongest argument for ARDT centers on Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : ARDT
The primary concerns for ARDT are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 1.68 is elevated, increasing financial risk. Thin 1.2% margins leave little buffer for downturns.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARDT profiles as a value stock while LLY is a growth play — different risk/reward profiles.
ARDT carries more volatility with a beta of 0.70 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 40/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ardent Health Partners, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Ardent Health Partners, Inc. is a leading healthcare organization based in Nashville, Tennessee, focused on providing high-quality, patient-driven care through an extensive network of hospitals and outpatient facilities. The company emphasizes innovation and operational excellence, offering a comprehensive range of acute care services tailored to the specific needs of the communities it serves. With a solid financial foundation and a strategic growth plan, Ardent is well-prepared to enhance healthcare access and improve patient outcomes in a dynamic healthcare environment.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?